Orthofix Medical Inc.: directors' dealings · United States · SEC (Form 4)

About Orthofix Medical Inc.

Orthofix Medical Inc. is a U.S.-based medical technology company listed on the NASDAQ under the ticker OFIX, with corporate headquarters in Lewisville, Texas, United States. For European investors, Orthofix should be viewed as a specialized orthopedics and spine company focused on complex musculoskeletal conditions rather than a broad-based medtech conglomerate. The company traces its roots to 1980 in Verona, Italy, and has since evolved through several corporate milestones, including a later re-domestication to the United States in 2018 and a transformative merger of equals with SeaSpine completed in January 2023. That combination broadened the group’s scale and sharpened its identity as a global spine and orthopedics platform. Orthofix’s portfolio is built around several complementary business lines: spinal implants, therapeutic solutions, limb reconstruction systems, biologics, and enabling technologies. Its product set includes spinal fixation systems, deformity correction solutions, bone growth therapies, limb reconstruction devices, and intraoperative navigation technologies such as the 7D FLASH Navigation System. Strategically, Orthofix occupies a niche position in the orthopedic medtech landscape. It is not the largest diversified player in the sector, but it competes on specialization, procedural relevance, surgeon relationships, and technology-led differentiation. The company’s competitive proposition is based on serving highly specific clinical needs where product performance, workflow efficiency, and surgical adoption matter materially. Geographically, Orthofix has a broad international footprint, with products sold in more than 60 countries and a meaningful commercial and operational presence in the United States. Its global reach is supported by a combination of direct sales, distributor relationships, and partnerships with clinical organizations. Management has emphasized a focus on spine commercial channel optimization, deeper penetration of enabling technologies, and continued development of the limb reconstruction and biologics franchises. This mix gives the company exposure to both mature and growth-oriented orthopedic subsegments. Recent developments have been important for the investment case. In February 2026, Orthofix reported full-year 2025 results and highlighted operational progress, improved adjusted EBITDA, and stronger free cash flow generation. In May 2026, the company reiterated guidance and said it was seeing steadier execution following spine commercial channel actions. Orthofix also announced the discontinuation of its M6 product lines, reallocating resources toward more profitable growth opportunities. At the same time, the company has been advancing launches and rollouts such as TrueLok Elevate and FITBONE, while continuing to focus on biologics and navigation technologies. Overall, Orthofix remains a specialized medtech name with a clear portfolio focus, international exposure, and a turnaround-and-growth narrative driven by product innovation, commercial execution, and margin improvement.